Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by itntdfon Jan 04, 2024 9:00pm
171 Views
Post# 35811653

RE:RE:RE:San Diego

RE:RE:RE:San Diegowhat i would expect is for the investor relations contact who had his number listed on the bottom of the press release (presumably so that investors could contact him) to say they are in a blackout period, andrew was released and they have no further comment, there are things which can not be discussed about what is going on etc.

what i do not expect is for the ir person to ask "why is this of any interest to you" or "your questions are irrelevant" etc.

this guy is obviously not up to the job if he does not have reasonable responses to questions of legitimate interest to an investor.

as to "you caught me" must be hard to see with you head so far up your rear.  i have posted on yahoo under the id: oncolyte and haven't posted there in quite some time.  i post here under the id: itntdf.  when i held general growth stock during their bankruptcy and emergence, i posted under the id: justthefactsmam.  have visited stocktwits and not sure if i have posted there or not but if i did it probably would have been under the oncolyte id.

i've held this stock since well before 2014 and have over 40k shares. 
<< Previous
Bullboard Posts
Next >>